Cross Atlantic Partners

Cross Atlantic Partners (CAP) is a New York City based venture capital firm. They actively manage private equity funds for investment in developing healthcare and life sciences companies in the United States. They focus on later-stage private and public companies developing innovative drug discovery tools, devices, and services for human healthcare.

Cross Atlantic Partners has made 13 investments. Their most recent investment was on Jan 8, 2013, when Labcyte raised $5.3M. Other investments include QuesCom, Sapphire Digital, Filao, Mobile Digital Media and GQ Life Sciences.

Cross Atlantic Partners has had 6 exits. Cross Atlantic Partners's most notable exits include Labcyte, Acorda Therapeutics, and GQ Life Sciences.

Cross Atlantic Partners (CAP) is a New York City based venture capital firm. They actively manage private equityprivate equity funds for investment in developing healthcare and life sciences companies in the United States. They focus on later-stage private and public companies developing innovative drug discovery tools, devices, and services for human healthcare.

Cross Atlantic Partners has made 13 investments. Their most recent investment was on Jan 8, 2013, when LabcyteLabcyte raised $5.3M. Other investments include QuesCom, Sapphire Digital, Filao, Mobile Digital Media and GQ Life Sciences.

Cross Atlantic Partners (CAP) is a New York CityNew York City based venture capital firm. They actively manage private equity funds for investment in developing healthcare and life sciences companies in the United States. They focus on later-stage private and public companies developing innovative drug discovery tools, devices, and services for human healthcare.

Cross Atlantic Partners (CAP) is a New York City based venture capital firm. They actively manage private equity funds for investment in developing healthcare and life sciences companies in the United StatesUnited States. They focus on later-stage private and public companies developing innovative drug discovery tools, devices, and services for human healthcare.

Cross Atlantic Partners has had 6 exits. Cross Atlantic Partners's most notable exits include Labcyte, Acorda TherapeuticsAcorda Therapeutics, and GQ Life Sciences.